Society of Nuclear Medicine and Molecular Imaging
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), formerly the Society of Nuclear Medicine, is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI's mission is to improve human health by advancing molecular imaging and therapy.
Formation | 1954 |
---|---|
Type | Professional association |
Headquarters | 1850 Samuel Morse Drive, Reston, VA 20190 |
Membership | 19,000 |
Key people | Virginia Pappas, CAE, CEO |
Budget | $10.8 million |
Staff | 50 |
Website | www |
The SNMMI was founded in 1954 as the Society of Nuclear Medicine,[1] under the sponsorship of the Pacific Northwest Society of Nuclear Medicine.[2] The name was changed to include molecular imaging in 2012.[3] SNMMI has 15,000 members,[4] consisting of nuclear and molecular imaging professionals worldwide. Members include physicians, technologists, physicists, pharmacists, scientists, laboratory professionals and more.
The SNMMI national headquarters is located in Reston, Virginia, and 12 state/regional chapters are located throughout the United States and Canada. As a volunteer organization, SNMMI is governed by a policy-making board of directors, a house of delegates, committees and councils.
Publications
editSNMMI's flagship journal, The Journal of Nuclear Medicine, ranked seventh in its category in 2020 according to its CiteScore.[5] The Journal of Nuclear Medicine Technology focuses specifically on issues of interest to technologists. In addition, SNMMI publishes a number of books, newsletters and other products of interest to its members.
Education and research
editSNMMI's Annual Meeting and Mid-Winter Meeting provide the nuclear and molecular imaging community with education programs on the latest advances in the field. SNMMI also offers Maintenance of Certification courses as well as live and online learning opportunities through its Learning Center.
SNMMI provides a forum in which researchers and physicians can communicate and collaborate to speed the process of evaluating scientific and clinical research and integrating it into clinical practice.
Advocacy
editOn behalf of its members, SNMMI advocates for improved policies and legislation for research, funding and reimbursement for molecular imaging. SNMMI also works with its members to develop practice guidelines and accreditation standards.
Outreach
editSNMMI is involved in educating patients and referring physicians about nuclear medicine and molecular imaging. A Patient Advocacy Advisory Board was created to guide the society's outreach efforts. The board includes the Alzheimer's Association, the American Thyroid Association, the Leukemia and Lymphoma Society, the Ovarian Cancer National Alliance, the American Heart Association, the Men's Health Network, NorCal CarciNET Community and the Thyroid Cancer Survivors' Association. One of the main projects of the board was the development of a patient-oriented website, DiscoverMI.org.[6]
See also
editReferences
edit- ^ Budinger, Thomas Francis; Jones, Terry (2014). "History of Nuclear Medicine and Molecular Imaging". In Brahme, Anders (ed.). Comprehensive biomedical physics. Amsterdam: Elsevier. p. 23. doi:10.1016/B978-0-444-53632-7.00101-5. ISBN 978-0-444-53633-4.
- ^ Harris, C. Craig (July 1996). "The formation and evolution of the society of nuclear medicine". Seminars in Nuclear Medicine. 26 (3): 180–190. doi:10.1016/S0001-2998(96)80023-7. PMID 8829279.
- ^ "SNM Changing Name to Society of Nuclear Medicine and Molecular Imaging". Oncology Times. 34 (15): 22. August 2012. doi:10.1097/01.COT.0000418799.52676.f9.
- ^ "About SNMMI". SNMMI. Retrieved 13 February 2021.
- ^ "Source details - Journal of Nuclear Medicine". Scopus. Elsevier. Retrieved 13 February 2021.
- ^ Pappas, Virginia (October 2011). "Reaching outside of our community". Journal of Nuclear Medicine. 52 (10): 32N. PMID 21969403.